Highlights
Natural menopause before age 40 was associated with an approximately 40% higher lifetime risk of coronary heart disease in both Black and White women.
Premature menopause was substantially more common in Black women than in White women in this pooled cohort analysis, affecting 15.5% versus 4.8%, respectively.
Women with premature menopause tended to live fewer years free of coronary heart disease, although differences in restricted mean survival time were modest and not statistically significant across groups.
The findings reinforce premature menopause as a clinically relevant risk-enhancing factor that should be routinely elicited when estimating long-term cardiovascular risk in women.
Background
Cardiovascular disease remains the leading cause of death in women, yet sex-specific risk markers are still underused in routine prevention. Menopause has long been recognized as a major biological transition associated with adverse changes in lipids, vascular function, body composition, insulin sensitivity, and inflammatory signaling. Among menopause-related characteristics, premature menopause, generally defined as natural menopause before age 40 years, has emerged as a particularly important marker of accelerated cardiometabolic aging.
Prior studies have shown that earlier menopause is linked to a higher short-term risk of coronary heart disease, stroke, heart failure, and all-cause mortality. However, clinicians often need more than short-term hazard estimates. They need information that can inform life-course counseling: What is the absolute lifetime risk? How many years might a woman live free of coronary heart disease? Does the association appear similar across racial groups? These are especially relevant questions because cardiovascular risk is shaped not only by biology, but also by structural and social determinants that differ across populations.
The study by Freaney and colleagues addresses an important gap by estimating lifetime coronary heart disease risk associated with premature natural menopause and examining whether this relationship differs between Black and White women. This approach moves the conversation from relative risk alone toward clinically meaningful measures that may better support patient communication and preventive decision-making.
Study Design and Methods
Design and data sources
This was a prospective population-based cohort study pooling individual-level data from 6 US cohorts, with follow-up spanning 1964 to 2018 and totaling 163,600 person-years. The analysis included postmenopausal women aged 55 to 69 years at baseline who self-identified as Black or White, had no coronary heart disease at study entry, and had available information on menopausal status and coronary heart disease outcomes.
Population
The final sample comprised 3,522 Black women and 6,514 White women. Mean baseline age was 61.2 years in Black women and 60.0 years in White women. Women with surgically induced menopause were excluded to isolate the association of natural menopause timing with later coronary heart disease risk.
Exposure
The exposure of interest was premature natural menopause, defined as menopause before age 40 years.
Outcome
The primary outcome was incident coronary heart disease, defined as fatal or nonfatal myocardial infarction. The study also accounted for competing risk from non-coronary death, an important step in lifetime risk estimation because death from other causes can prevent the occurrence of coronary events.
Statistical approach
The investigators used three complementary methods. First, modified Kaplan-Meier analyses were used to estimate lifetime coronary heart disease risk. Second, adjusted competing-risk Cox models were applied to estimate the joint cumulative risks of coronary heart disease and non-coronary death. Third, Irwin restricted mean survival time methods were used to estimate mean years lived free of coronary heart disease and mean years lived with coronary heart disease. This framework is clinically helpful because it translates epidemiologic associations into years of healthy life.
Key Results
Premature menopause was more common in Black women
A notable finding was the marked difference in prevalence of premature menopause by self-identified race. Among Black women, 545 of 3,522, or 15.5%, experienced premature natural menopause. Among White women, 313 of 6,514, or 4.8%, did so. Even before considering coronary outcomes, this disparity is clinically important because it suggests that a larger proportion of Black women may enter a higher-risk reproductive aging phenotype.
Higher lifetime coronary heart disease risk in both racial groups
Premature menopause was associated with a significantly higher lifetime risk of incident coronary heart disease in both Black and White women. The hazard ratio was 1.41 (95% CI, 1.04-1.90) for Black women and 1.39 (95% CI, 1.03-1.87) for White women. The similarity of these estimates is striking. It suggests that once premature natural menopause occurs, its association with long-term coronary risk is of comparable magnitude across these two populations.
These are not trivial effect sizes. A 40% increase in lifetime coronary heart disease risk places premature menopause in the category of clinically meaningful risk-enhancing factors, especially when considered alongside traditional variables such as hypertension, diabetes, smoking, and dyslipidemia.
Years lived free of coronary heart disease
The restricted mean survival time analysis offered a more patient-centered view. Black women with premature menopause were estimated to live 18.2 years (95% CI, 17.5-18.9) free of coronary heart disease compared with 19.1 years (95% CI, 18.8-19.4) for Black women without premature menopause. A similar directional pattern was observed in White women. However, these differences did not reach statistical significance.
Although the restricted mean survival time findings were not definitive, the direction of effect was consistent with the main hazard-based analyses. This matters clinically: even when event-count differences are modest, an earlier transition into coronary heart disease risk may influence the timing and intensity of preventive interventions.
Clinical Interpretation
The main message is straightforward. Menopause history is not merely reproductive history; it is cardiovascular history. This study adds weight to the concept that natural menopause before age 40 identifies women at higher long-term risk for coronary heart disease, independent of whether they identify as Black or White.
Current prevention frameworks increasingly acknowledge female-specific risk enhancers. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease lists premature menopause, defined as menopause before age 40 years, among risk-enhancing factors that can support more intensive risk discussion and management. The present study strengthens that recommendation by showing the association is not limited to short-term follow-up and persists when viewed across the remainder of the lifespan.
For practicing clinicians, the implications are practical. Menopause timing should be routinely documented in cardiovascular risk assessment, just like pregnancy complications, smoking history, or family history of premature atherosclerotic disease. In women with premature menopause, clinicians should have a lower threshold to assess lifetime risk, optimize blood pressure and lipid control, reinforce smoking cessation, address diabetes prevention, and discuss diet, physical activity, sleep, and weight management. In selected patients, the presence of premature menopause may also support earlier use of additional risk-stratification tools, such as coronary artery calcium scoring, when treatment decisions remain uncertain.
Mechanistic Context
The biological plausibility of the association is strong. Earlier loss of ovarian function shortens cumulative exposure to endogenous estrogens, which have favorable effects on endothelial function, vascular reactivity, and lipid metabolism. Premature menopause has also been linked with higher LDL cholesterol, central adiposity, insulin resistance, and chronic low-grade inflammation. These pathways may accelerate atherosclerosis over decades.
At the same time, menopause timing may also reflect broader upstream processes rather than acting as a sole causal driver. Genetics, autoimmune conditions, tobacco exposure, socioeconomic adversity, psychosocial stress, and barriers to preventive care may all contribute to both earlier ovarian aging and later cardiovascular disease. In this way, premature menopause may function as both a biological event and a clinical marker of accumulated vulnerability.
Strengths and Limitations
Strengths
This study has several strengths. It pooled data from multiple established US cohorts and accrued long follow-up, allowing estimation of lifetime risk rather than short-term event rates alone. The exclusion of surgically induced menopause improved etiologic clarity by focusing on natural menopause. The use of competing-risk methods and restricted mean survival time adds clinical interpretability beyond conventional hazard ratios.
Limitations
Several limitations deserve attention. First, menopause timing was based on cohort data that may include self-report, raising the possibility of recall misclassification. Second, the analysis included only women who self-identified as Black or White, limiting generalizability to other racial and ethnic groups. Third, residual confounding remains possible, particularly from social determinants of health, smoking intensity, reproductive factors, and access to care across the life course. Fourth, the primary outcome was myocardial infarction-based coronary heart disease and may not capture the full spectrum of ischemic heart disease. Finally, as an observational study, the work cannot prove that premature menopause directly causes coronary heart disease; it shows a robust association.
Implications for Practice and Policy
The study supports a simple but often missed clinical action: ask every midlife and older woman at what age natural menopause occurred. This question is low-cost, fast, and potentially high-yield. If menopause occurred before age 40, clinicians should recognize the patient as having a higher lifetime cardiovascular risk burden.
These findings also intersect with health equity. Because premature menopause was more common among Black women in this analysis, routine assessment may identify risk earlier in populations already carrying disproportionate cardiovascular disease burden. That does not mean menopause timing fully explains racial disparities in coronary outcomes, but it may be one clinically actionable component within a broader prevention strategy.
From a systems perspective, menopause history should be integrated more consistently into electronic health records and cardiovascular prevention workflows. Risk calculators still do not fully incorporate many female-specific factors. Better integration of reproductive history into cardiovascular care pathways could improve personalization of prevention.
Conclusion
Freaney and colleagues provide clinically relevant evidence that premature natural menopause is associated with a roughly 40% higher lifetime risk of coronary heart disease in both Black and White women. The finding is important not only because it confirms prior concerns about early menopause and cardiovascular risk, but because it frames the issue in lifetime terms that matter to patients and clinicians alike.
The take-home point is clear: premature menopause should be treated as a routine cardiovascular risk-enhancing factor. Its identification should prompt more careful risk assessment, more proactive prevention, and closer attention to the cardiovascular health of women across the life course. Future studies should examine other racial and ethnic groups, clarify mechanisms, and test whether menopause-informed prevention strategies improve outcomes.
Funding and ClinicalTrials.gov
The abstract provided does not report a funding source. No ClinicalTrials.gov registration number is listed, which is expected for an observational pooled cohort analysis rather than an interventional trial.
References
1. Freaney PM, Ning H, Carnethon M, Wilkins JT, Allen NB, Lloyd-Jones DM, Khan SS. Premature Menopause and Lifetime Risk of Coronary Heart Disease. JAMA Cardiology. 2026;11(5):455-458. PMID: 41848694.
2. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation. 2019;140(11):e596-e646. PMID: 30879355.
3. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. PMID: 24084921.
4. Honigberg MC, Zekavat SM, Aragam K, et al. Association of Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. JAMA. 2019;322(24):2411-2421. PMID: 31841581.
5. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention. Circulation. 2020;142(25):e506-e532. PMID: 33297817.